{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T21:51:45Z","timestamp":1770155505477,"version":"3.49.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.transproceed.2017.12.015","type":"journal-article","created":{"date-parts":[[2018,2,3]],"date-time":"2018-02-03T00:36:29Z","timestamp":1517618189000},"page":"66-69","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Eculizumab for Prevention of Antibody-Mediated Rejection in Blood Group-Incompatible Renal Transplantation"],"prefix":"10.1016","volume":"50","author":[{"given":"P.","family":"West-Thielke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Progar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Campara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Jasiak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Gallon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Spaggiari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Tzvetanov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Benedetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2017.12.015_bib1","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.2146\/ajhp080043","article-title":"Eculizumab","volume":"65","author":"Davis","year":"2008","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.transproceed.2017.12.015_bib3","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1182\/blood-2016-08-732800","article-title":"Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation","volume":"129","author":"Harder","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.transproceed.2017.12.015_bib4","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.molimm.2016.07.016","article-title":"Eculizumab epitope on complement C5: progress towards a better understanding of the mechanism of action","volume":"77","author":"Brachet","year":"2016","journal-title":"Mol Immunol"},{"key":"10.1016\/j.transproceed.2017.12.015_bib5","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/tri.12706","article-title":"Complement inhibition as potential new therapy for antibody-mediated rejection","volume":"29","author":"Eskandary","year":"2016","journal-title":"Transpl Int"},{"key":"10.1016\/j.transproceed.2017.12.015_bib6","doi-asserted-by":"crossref","first-page":"E216","DOI":"10.1111\/ctr.12102","article-title":"The use of eculizumab in renal transplantation","volume":"27","author":"Barnett","year":"2013","journal-title":"Clin Transplant"},{"key":"10.1016\/j.transproceed.2017.12.015_bib7","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/MOT.0000000000000249","article-title":"Eculizumab use in kidney transplantation","volume":"20","author":"Johnson","year":"2015","journal-title":"Curr Opin Organ Transplant"},{"key":"10.1016\/j.transproceed.2017.12.015_bib8","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.transproceed.2015.11.028","article-title":"Complement inhibition for prevention and treatment of antibody-mediated rejection in renal allograft recipients","volume":"48","author":"Jordan","year":"2016","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2017.12.015_bib9","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/trf.12882","article-title":"Successful use of eculizumab for treatment of an acute hemolytic reaction after ABO-incompatible red blood cell transfusion","volume":"55","author":"Weinstock","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.transproceed.2017.12.015_bib10","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1111\/trf.13119","article-title":"Eculizumab inhibits hemolysis in a model of ABO-incompatible red blood cell transfusion","volume":"55","author":"Fata","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.transproceed.2017.12.015_bib11","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/TP.0b013e318245b2af","article-title":"Outcomes of ABO-incompatible kidney transplantation in the United States","volume":"93","author":"Montgomery","year":"2012","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.transproceed.2017.12.015_bib12","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/tri.12507","article-title":"Titer rebound after ABO-incompatible kidney transplantation\u2014is all accommodated for?","volume":"28","author":"Boger","year":"2015","journal-title":"Transpl Int"},{"key":"10.1016\/j.transproceed.2017.12.015_bib13","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1111\/j.1600-6143.2010.03103.x","article-title":"ABO antibody titer and risk of antibody-mediated rejection in ABO-incompatible renal transplantation","volume":"10","author":"Tobian","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2017.12.015_bib14","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/tri.12482","article-title":"Postoperative rebound of antiblood type antibodies and antibody-mediated rejection after ABO-incompatible living-related kidney transplantation","volume":"28","author":"Ishida","year":"2015","journal-title":"Transpl Int"},{"key":"10.1016\/j.transproceed.2017.12.015_bib15","first-page":"9874261","article-title":"Eculizumab for the treatment of severe antibody-mediated rejection: a case report and review of the literature","volume":"2016","author":"Tran","year":"2016","journal-title":"Case Rep Transplant"},{"key":"10.1016\/j.transproceed.2017.12.015_bib16","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/j.transproceed.2016.03.028","article-title":"Dosing eculizumab for antibody-mediated rejection in kidney transplantation: a case report","volume":"48","author":"Smith","year":"2016","journal-title":"Transplant Proc"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134517308710?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134517308710?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T11:15:01Z","timestamp":1635506101000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134517308710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0041134517308710"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2017.12.015","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eculizumab for Prevention of Antibody-Mediated Rejection in Blood Group-Incompatible Renal Transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2017.12.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}